ARTICLE SUMMARY:
The diabetes device market is at a crossroads. Strong demand for continuous glucose monitors, automated insulin delivery systems, and other “smart” offerings such as pens and apps is driving double-digit revenue growth while at the same time, competitive pressures and the potential for GLP-1 headwinds are infusing some uncertainty into the marketplace. In this climate, companies are seeking an edge, and acquisitions, IP battles, and other market bolstering efforts are all part of the game.
